臨床婦人科産科72巻6号

2018年06月発行

今月の臨床 がん免疫療法の新展開─「知らない」ではすまない今のトレンド

がん免疫療法の分類と作用機序

がんワクチン療法とは何か

著者： 馬淵誠士¹ 甲村奈緒子¹ 横井恵理子¹ 木村正¹

所属機関： ¹大阪大学大学院医学系研究科産科学婦人科学講座

ページ範囲：P.542 - P.549

文献概要

●がんワクチン療法は，がん抗原を投与することにより，患者体内で，がん抗原に対する特異的な免疫応答を誘導し，がん細胞を排除しようとする治療法である．

●がん免疫療法は，手術，化学療法，放射線療法に次ぐ治療法として期待されているが，がんワクチン療法単独での臨床効果はいまだ不十分である．

●がん治療ワクチンと，免疫抑制因子（免疫チェックポイント分子や骨髄由来抑制細胞）を排除する治療を組み合わせた“複合的がん免疫療法”に期待が高まっている．

参考文献

1）Hu Z, et al : Towards personalized, tumour-specific, therapeutic vaccines for cancer. Nat Rev Immunol 18 : 168─182, 2017

2）Cheever MA, et al : The prioritization of cancer antigens : a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 15 : 5323─5337, 2009

3）Sakamoto S, et al : Prospect and progress of personalized peptide vaccinations for advanced cancers. Expert Opin Biol Ther 16 : 689─698, 2016

4）Alexandrov LB, et al : Signatures of mutational processes in human cancer. Nature 500 : 415─421, 2013

5）Kantoff PW, et al : Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363 : 411─422, 2010

6）Matsumoto Y, et al : The significance of tumor-associated neutrophil density in uterine cervical cancer treated with definitive radiotherapy. Gynecol Oncol 145 : 469─475, 2017

7）Mabuchi S, et al : Uterine cervical cancer displaying tumor-related leukocytosis : a distinct clinical entity with radioresistant feature. J Natl Cancer Inst 106 : pii : dju147, 2014

8）Cui TX, et al : Myeloid-derived suppressor cells enhance stemness of cancer cells by inducing microRNA101 and suppressing the corepressor CtBP2. Immunity 39 : 611─621, 2013

9）Chesney JA, et al : Myeloid-derived suppressor cells-a new therapeutic target to overcome resistance to cancer immunotherapy. J Leukoc Biol 102 : 727─740, 2017

10）Kuroda H, et al : PM01183 inhibits myeloid-derived suppressor cells in vitro and in vivo. Immunotherapy 9 : 805─817, 2017

11）Hardwick NR, et al : p53-reactive T cells are associated with clinical benefit in patients with platinum-resistant epithelial ovarian cancer after treatment with a p53 vaccine and gemcitabine chemotherapy. Clin Cancer Res 24 : 1315─1325, 2018

12）Rahma OE, et al : A gynecologic oncology group phase ii trial of two p53 peptide vaccine approaches : Subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients. Cancer Immunol Immunother 61 : 373─384, 2012

13）Leffers N, et al : Immunization with a p53 synthetic long peptide vaccine induces p53-specific immune responses in ovarian cancer patients, a phase II trial. Int J Cancer 125 : 2104─2113, 2009

14）Odunsi K, et al : Efficacy of vaccination with recombinant vaccinia andfowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanomapatients. Proc Natl Acad Sci U S A 109 : 5797─802, 2012

15）Miyatake T, et al : WT1 peptide immunotherapy for gynecologic malignancies resistant toconventional therapies : a phase II trial. J Cancer Res Clin Oncol 139 : 457─463, 2013